<DOC>
	<DOC>NCT02451098</DOC>
	<brief_summary>A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Factorial Design, Phase III Clinical Trial.</brief_summary>
	<brief_title>Clinical Trial to Evaluate the Efficacy and Safety of CKD-391</brief_title>
	<detailed_description>The aim of this phase 3 study was to evaluate the efficacy and safety of CKD-391 once daily for 8 weeks in patients with primary hypercholesterolemia. Furthermore, the extension study for additional 12 weeks is designed to confirm long term safety of CKD-391.</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Adult, at least 19 years of age. Hyperlipidemia patient of LDLC≤250 mg/dl and TG ≤400 mg/dl Patients requiring antidyslipidemia drug therapy [based on the NCEP ATP III(2002)] Drug compliance during Runin period ≥70% Patients must willing to the study and signed an informed consent Patients with myopathy included rhabdomyolysis or CPK level≥2xULN Patients with acute arterial disease Patients with renal dysfunction or Serum creatinine level ≥2x ULN Patients with liver dysfunction or ALT, AST level &gt; 2xULN Patients with medical history within 6 months prior to screening visit (Heart failure, uncontrolled arrhythmia, drug and alcohol abuse history, gastrointestinal disease or surgery, anticoagulation disease) Patient with uncontrolled disease (diabetes mellitus as HbA1c level of &gt; 9.0%, hypertension as SBP≥180mmHg or DBP≥110mmHg, hypothyroidism as TSH≥1.5xULN) Patients who have a history or presence of active malignancy within 5 years Patients with difficulty of stop taking lipidlowering agents during runin period. Patients who have taken another investigational drug within 4 weeks prior to screening visit.</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>